sb 216763 has been researched along with Carcinoma, Medullary in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, H; Kunnimalaiyaan, M; Ndiaye, MA; Vaccaro, AM | 1 |
1 other study(ies) available for sb 216763 and Carcinoma, Medullary
Article | Year |
---|---|
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Topics: Adjuvants, Immunologic; Animals; Apoptosis; Carcinoma, Medullary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Lithium Chloride; Maleimides; Mice; Mice, Nude; NIH 3T3 Cells; Phosphorylation; Proto-Oncogene Proteins c-raf; Signal Transduction; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2007 |